Latest News

Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL
Real-World Data Suggest Favorable Outcomes With Post-Axi-Cel Administration in R/R LBCL

December 10th 2023

Although the use of bridging therapy prior to treatment with axicabtagene ciloleucel did not improve efficacy or safety outcomes for patients with relapsed/refractory large B-cell lymphoma, responses to bridging therapy may be prognostic of favorable outcomes after axi-cel administration.

Real-World Evidence Highlights Brexu-cel's Safety and Efficacy in Mantle Cell Lymphoma Patients
Real-World Evidence Highlights Brexu-cel's Safety and Efficacy in Mantle Cell Lymphoma Patients

December 9th 2023

FDA Approves Pirtobrutinib in CLL and SLL
FDA Approves Pirtobrutinib in CLL and SLL

December 4th 2023

GLS1 With BCL-2 Presents New Treatment Potential in DLBCL
GLS1 With BCL-2 Presents New Treatment Potential in DLBCL

November 30th 2023

FDA Grants Epcoritamab Breakthrough Drug Designation for FL
FDA Grants Epcoritamab Breakthrough Drug Designation for FL

November 27th 2023

More News